Form 4: Astria Therapeutics' Chief Medical Officer Granted Stock Options

Christopher Morabito, Chief Medical Officer of Astria Therapeutics, received stock options for 262,500 shares on March 21, 2025, vesting over four years.

Summary

• Christopher Morabito, the Chief Medical Officer of Astria Therapeutics, Inc. (ATXS), was granted stock options on March 21, 2025.
• The options are for 262,500 shares of Astria Therapeutics common stock.
• The exercise price of the options is $6.41 per share.
• The options vest over a four-year period, starting with 25% vesting on the first anniversary of February 13, 2025, and the remainder vesting in equal monthly installments over the following three years.
• The options expire on March 20, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Future Outlook

This document does not contain any forward-looking statements or guidance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant is typical for a company of Astria Therapeutics' size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use stock options extensively to incentivize their leadership teams.
• The vesting schedule of four years with a one-year cliff is also a common practice, aligning with industry norms.

Stakeholder Impact

• Shareholders: The grant of stock options aligns management's interests with those of shareholders, potentially driving long-term value creation.
• Employees: The grant could boost employee morale by demonstrating the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Astria Therapeutics, ATXS, Chief Medical Officer, Christopher Morabito, Form 4, insider trading